Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?

Nature Reviews Nephrology

Volumn 9, Issue 3, 2013, Pages 128-130

  Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE METHYL; DH 404; RAMIPRIL; RTA 405; UNCLASSIFIED DRUG;

DIABETIC NEPHROPATHY; DISEASE MODEL; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FOOD INTAKE; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; EARLY TERMINATION OF CLINICAL TRIALS; GLOMERULAR FILTRATION RATE; HUMANS; OLEANOLIC ACID;

EID: 84874653586     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.13     Document Type: Review

References (10)

1. Pergola, P. E. et al. Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD. Am. J. Nephrol. 33, 469-476 (2011).
2. Pergola, P. E. et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 (2011).
3. Zoja, C. et al. Analogues of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Renal Physiol. http://dx.doi.org/doi:10.1152/ajprenal.00376.2012.
4. Wu, Q. Q. et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARgamma, and HO-1. Am. J. Physiol. Renal Physiol. 300, F1180-F1192 (2011).
5. Aleksunes, L. M. et al. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 335, 2-12 (2010).
6. Rossing, P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 49, 11-19 (2006).
7. McMahon, G. M. & Forman, J. P. Bardoxolone methyl, chronic kidney disease, and type 2 diabetes. N. Engl. J. Med. 365, 1746-1747 (2011).
8. Reata Pharmaceuticals. Company Statement: Termination of the BEACON Trial [online], http://www.reatapharma.com/investors-media/news/news-timeline/2012/ company-statement-termination-of-beacon-trial.aspx (2012).
9. Rossing, P., Hommel, E., Smidt, U. M. & Parving, H.-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37, 511-516 (1994).
10. de Zeeuw, D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin. Nephrol. 27, 172-181 (2007).